# Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula

> **NCT00992485** · PHASE1 · COMPLETED · sponsor: **Anterogen Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Crohn's Fistula

## Interventions

- **DRUG:** ADIPOPLUS

## Key facts

- **NCT ID:** NCT00992485
- **Lead sponsor:** Anterogen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-09
- **Final completion:** 2010-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2010-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992485, "Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00992485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*